Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...
TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...
BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...
A lot of Amgen’s future rides on its experimental obesity medicine MariTide. At least in the minds of investors.
Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its ...
Syros Pharmaceuticals’ share price nosedived after its last drug candidate flunked a trial in hematological ...
Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...
Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...
Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...
Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...
AstraZeneca CEO Pascal Soriot affirms commitment to China despite investigation involving China president Leon Wang and other employees. Wang, who reported directly to Soriot, and former AstraZeneca ...
Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several preclinical ...